Today: 21 June 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Devon Energy Shares Climb After $8 Billion Buyback

Devon Energy Shares Climb After $8 Billion Buyback

Devon Energy shares closed up 4.76% at $49.49 Friday after oil prices rallied, with Brent settling at $109.26 and WTI at $105.42 amid Strait of Hormuz concerns. The move follows Devon’s completion of its Coterra merger and approval of an $8 billion share buyback. Trading volume reached about 16.5 million shares. Devon’s stock remains below its 52-week high of $52.71.
16 May 2026
····
UnitedHealth Stock Watches Berkshire Exit, Optum AI Effort

UnitedHealth Stock Watches Berkshire Exit, Optum AI Effort

Berkshire Hathaway sold its entire UnitedHealth Group stake in the first quarter, less than a year after buying 5.04 million shares. UnitedHealth shares closed at $393.85 Friday, down 1.3%. Bloomberg reported UnitedHealth is tracking some Optum workers’ use of AI tools as it expands technology in operations. Analysts say insurers need another quarter of clean medical-cost data before judging recovery.
16 May 2026
··
Gold Drops on Dollar Gains, Wall Street Sinks as Yields Jump

Gold Drops on Dollar Gains, Wall Street Sinks as Yields Jump

The dollar rose for a fifth day Friday, pushing gold to a one-week low and sending the euro to $1.1623, its weakest in five weeks. U.S. crude jumped 4.2% to $105.42 a barrel amid concerns over the Strait of Hormuz. The 10-year Treasury yield hit an 11.75-month high at 4.58%, while the Nasdaq ended a six-week winning streak. Silver plunged 7.7% to $77.07 an ounce.
16 May 2026
·
TD Securities Filing Throws Spotlight on GCT Semiconductor (GCTS), Raises Flags About 5G Chip Scale-Up and Liquidity

TD Securities Filing Throws Spotlight on GCT Semiconductor (GCTS), Raises Flags About 5G Chip Scale-Up and Liquidity

TD Securities (USA) LLC disclosed a 4.6% beneficial ownership in GCT Semiconductor Holding, Inc., mostly via warrants exercisable at $11.50 a share, far above Friday’s $1.83 stock price. GCT reported first-quarter revenue of $1.92 million and a net loss of $9.86 million, with 5G chipset deliveries rising 58% to 3,000 units.
15 May 2026
··
Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharmaceuticals filed new Phase 1 modeling data showing its experimental Lyme disease antibody, TNX-4800, could maintain serum levels above a proposed protective threshold for six months with a two-dose regimen. Shares rose $1.65 to $15.74 Friday. The company plans a Phase 2 trial in 2027, pending FDA agreement. No Lyme vaccine is currently available in the U.S.
15 May 2026
···
Lululemon CEO Speaks Out as Shares Drop Again

Lululemon CEO Speaks Out as Shares Drop Again

Lululemon shares fell 1.6% to $119.14 Friday as incoming CEO Heidi O’Neill told employees the company is being underestimated. Founder Chip Wilson is seeking three board seats, intensifying a proxy fight ahead of O’Neill’s September 8 start. O’Neill, a former Nike executive, will not be on the ballot at the June annual meeting. Investors remain focused on weak Americas sales and soft 2026 guidance.
15 May 2026
·
Ballard Power stock jumps after Weichai share sale leads to board shake-up

Ballard Power stock jumps after Weichai share sale leads to board shake-up

Weichai-affiliated holders reduced their stake in Ballard Power Systems to 11.61%, triggering the loss of board nomination rights and prompting the resignation of two Weichai-nominated directors. Ballard’s Nasdaq shares jumped 8.5% to $4.48 on heavy volume after the disclosure. Weichai sold over 11 million shares in recent weeks and filed to sell up to 15 million more. Ballard reported Q1 revenue of $19.4 million, up 26%.
15 May 2026
·
P3 Health Partners turns profit in Q1, lifts 2026 forecast

P3 Health Partners turns profit in Q1, lifts 2026 forecast

P3 Health Partners shares surged over 200% to $13.00 Friday after the company posted its first quarterly profit and raised its 2026 adjusted EBITDA outlook. Net income reached $3 million versus a $44.2 million loss a year earlier, with revenue up 4% to $386 million despite a 10% drop in at-risk membership. The company cited $17 million in one-time benefits, leaving underlying adjusted EBITDA at $8 million.
15 May 2026
··
AT&T, Verizon, T-Mobile Rally Against Dead Zones With Uncommon Satellite Move, Eye Starlink Push

AT&T, Verizon, T-Mobile Rally Against Dead Zones With Uncommon Satellite Move, Eye Starlink Push

AT&T, Verizon, and T-Mobile announced plans to jointly build a satellite-based network to eliminate U.S. wireless dead zones, aiming to connect ordinary phones directly to satellites. The move follows the FCC’s approval of EchoStar’s $40 billion spectrum sale to SpaceX and AT&T. The carriers have an agreement in principle but have not finalized terms. AT&T reported $31.5 billion in Q1 revenue and $126.4 billion in net debt.
15 May 2026
·····
UBS Reduces Exposure to Ambev After Strong Run in Brazil Beer Stocks

UBS Reduces Exposure to Ambev After Strong Run in Brazil Beer Stocks

Ambev’s São Paulo shares fell 0.25% to 15.73 reais Friday, despite UBS raising its target price but maintaining a Sell rating. First-quarter profit rose 2.1% to 3.89 billion reais, with Brazil Beer volumes hitting a record and net revenue up 9.6%. Cash flow surged 162.5% to 3.16 billion reais. Consolidated cash cost of goods sold per hectoliter climbed 8.5%.
15 May 2026
·
Pfizer Inc Looks to India, but Investors Hold Off

Pfizer Inc Looks to India, but Investors Hold Off

Pfizer is increasing investment in India for cancer drugs, obesity treatments, and vaccines as it seeks growth beyond COVID-era sales. The company reported Q1 revenue of $14.5 billion, up 5%, but expects a $1.5 billion hit this year from generic competition. Shares fell 1.8% to $25.29 in New York trading. In Europe, Pfizer won expanded approval for its hemophilia drug Hympavzi.
15 May 2026
·
Shares of BigBear.ai Slide as Defense AI Hype Wavers

Shares of BigBear.ai Slide as Defense AI Hype Wavers

BigBear.ai shares fell about 5% to $4.16 Friday afternoon after reporting flat first-quarter revenue of $34.4 million and a wider adjusted EBITDA loss of $9.9 million. Backlog rose 14% to $281.9 million, boosted by a $53 million classified contract. The company kept its 2026 revenue forecast at $135 million to $165 million. Gross margin improved to 34.0% from 21.3% a year earlier.
15 May 2026
···
Oil prices rise after Trump issues Iran warning

Oil prices rise after Trump issues Iran warning

Brent crude rose above $109 a barrel Friday after President Trump warned he was losing patience with Iran, raising fears the Strait of Hormuz could stay mostly shut. U.S. gasoline averaged over $4.50 a gallon. Stocks and bonds fell as traders braced for a longer energy shock. The S&P 500 dropped 0.8% and 10-year Treasury yields hit 4.568%.
15 May 2026
·
Palantir’s AI Work in Ukraine Draws PLTR Into Human-Rights Firestorm

Palantir’s AI Work in Ukraine Draws PLTR Into Human-Rights Firestorm

Palantir Technologies faces renewed investor pressure after shareholders representing $336.1 billion backed a call for an independent human-rights review of its software. The push comes as Palantir’s AI tools draw attention in Ukraine, where CEO Alex Karp signed a data-sharing deal with the military. Shareholders will vote on disclosure and rights proposals at the June 3 annual meeting. Palantir’s board opposes the measures.
15 May 2026
···
1 … 55 56 57 58 59 … 872

Stock Market Today

  • MercadoLibre Stock Drops Near 40% From Peak — Potential Buy Opportunity
    June 21, 2026, 9:27 AM EDT. MercadoLibre (MELI) stock has fallen nearly 40% from its all-time high amid rising competition and fintech challenges across Latin America. Despite a 49% revenue surge in Q1 2026, net income dropped 16%, hit by $1.24 billion in loan losses from its lending operations. The e-commerce and fintech company is addressing compressed margins and increasing bad loans by leveraging AI to improve borrower repayment. MercadoLibre's strong market position and moves to outlast smaller competitors could lead to higher market share in the long term. The current share price reflects these struggles but may present a buying opportunity for investors betting on the company's strategic resilience and growth prospects.

Latest articles

SpaceX Stock Risks Build as ARK ETF Flows, Retail Rules and Lockups Test IPO Rally

SpaceX Stock Risks Build as ARK ETF Flows, Retail Rules and Lockups Test IPO Rally

21 June 2026
SpaceX ended its first public week at $185, up 37% from its $135 IPO price but down from Tuesday’s $225.64 high, as index inclusion and ETF flows drive demand while looming lock-up releases and the first earnings report threaten new supply and volatility, with Moody’s, Fitch, and S&P giving investment-grade ratings but skeptics warning on valuation.
Germany faces pension reform tussle as costs for ageing, defence rise

Germany faces pension reform tussle as costs for ageing, defence rise

21 June 2026
Germany’s pension commission will propose raising the retirement age to 68 by 2051 and creating a state-run investment fund, forcing Chancellor Merz’s coalition to weigh later retirement, higher contributions, and market risk as Germany’s aging population strains public finances, Reuters and Handelsblatt report.
AbbVie-Apogee deal on radar for US healthcare stocks next week

AbbVie-Apogee deal on radar for US healthcare stocks next week

21 June 2026
AbbVie is reportedly nearing a $10.9 billion cash takeover of Apogee Therapeutics, offering a roughly 60% premium to Apogee’s Thursday close, with an announcement possible Monday; the deal puts both stocks at the center of Monday’s healthcare sector trading after a weak week for XLV, while risks remain as talks are unconfirmed and Apogee’s lead drug has not entered Phase 3 trials.
Go toTop